NCT07478029 Clinical Study of PEG Bowel Preparation in Appendectomy Patients
| NCT ID | NCT07478029 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Huaping Xie |
| Condition | Appendicitis |
| Study Type | OBSERVATIONAL |
| Enrollment | 10 participants |
| Start Date | 2024-02-23 |
| Primary Completion | 2027-02-23 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10 participants in total. It began in 2024-02-23 with a primary completion date of 2027-02-23.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Colonoscopy is a necessary item of physical examination for colorectal cancer. For high-risk groups, annual physical examination is the most effective way of early prevention; At present, a large amount of polyethylene glycol (PEG2000 - 4000) is often used as laxative and lubricant in colonoscopy. However, the widespread use of PEG may cause long-term and irreversible damage to intestinal microorganisms and bring great hidden dangers to health. The appendix has long been regarded as a redundant organ in evolution. The incidence of appendicitis ranks first in surgical acute abdomen. Traditionally, once acute appendicitis is diagnosed, it is usually treated with appendectomy. However, recent studies have revealed that appendectomy may be associated with psychiatric diseases, colorectal cancer, cardiovascular diseases and other diseases. The appendix is not only an important organ of the immune system, but also undertakes the function of storing and protecting intestinal microbes.. . This change may affect the function of the central nervous system through the microbe gut brain axis, and then pose a potential threat to the health and behavior of the host, such as increasing the risk of diseases such as Parkinson's disease. Based on this, this clinical trial aims to investigate (1) the changes of intestinal flora in the appendectomy population before and after colonoscopy in the process of polyethylene glycol intestinal preparation; (2) the differences between the changes of intestinal flora before and after colonoscopy in the appendicectomy population and the normal population in the process of flora recovery.
Eligibility Criteria
Inclusion Criteria: * Aged 18-75 years. * Scheduled to undergo colonoscopy. * Generally healthy without major organ diseases. 1. For appendectomy group: history of appendectomy or right hemicolectomy (including appendectomy). 2. For control group: no history of appendectomy or right hemicolectomy. Exclusion Criteria: * Allergy or intolerance to PEG laxatives. * Pregnant or lactating women. * Mental disorders. * Use of antibiotics within 6 months prior to study enrollment. 1. Contraindications to colonoscopy (e.g., severe cardiopulmonary insufficiency). 2. For control group only: presence of organic diseases.
Contact & Investigator
ping h Xie, Doctor
STUDY CHAIR
Tongji Medical College of Huazhong University of Science and Technology
Frequently Asked Questions
Who can join the NCT07478029 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Appendicitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07478029 currently recruiting?
Yes, NCT07478029 is actively recruiting participants. Contact the research team at hpxie@tjh.tjmu.edu.cn for enrollment information.
Where is the NCT07478029 trial being conducted?
This trial is being conducted at Wuhan, China.
Who is sponsoring the NCT07478029 clinical trial?
NCT07478029 is sponsored by Huaping Xie. The principal investigator is ping h Xie, Doctor at Tongji Medical College of Huazhong University of Science and Technology. The trial plans to enroll 10 participants.